海南医学
海南醫學
해남의학
HAINAN MEDICAL JOURNAL
2014年
23期
3451-3454
,共4页
代谢综合征%胰岛素抵抗%体质指数%利拉鲁肽
代謝綜閤徵%胰島素牴抗%體質指數%利拉魯肽
대사종합정%이도소저항%체질지수%리랍로태
Metabolic syndrome%Insulin resistance%Body mass index%Liraglutide
目的：探讨利拉鲁肽治疗血糖增高的代谢综合征的临床疗效。方法选取2012年1月至2014年1月我院收治的血糖增高的代谢综合征患者192例，按照随机数字表法分为观察组和对照组各96例，观察组和对照组均给予同样的饮食和运动方案，观察组给予利拉鲁肽治疗，对照组给予二甲双胍治疗，两组的疗程均为3个月。检测两组患者的空腹胰岛素、体质指数、血糖、血脂、血清脂联素等生化指标，计算稳态模型胰岛素抵抗指数(HOMA-IR)和总体胰岛素敏感指数(WBISI)并进行对比。结果治疗前，观察组和对照组患者在体质指数(BMI)、腰围(WC)、收缩压(SBP)、舒张压(DBP)、空腹血糖(FPG)、餐后2 h血糖(2 hPG)、空腹胰岛素(FINS)、甘油三脂(TG)、胆固醇(TC)、高密度脂蛋白-胆固醇(HDL-C)、低密度脂蛋白-胆固醇(LDL-C)、HOMA-IR、WBISI和血清脂联素方面比较差异均无统计学意义(P>0.05)；治疗后，观察组和对照组患者以上各指标均较治疗前明显改善，观察组改善明显优于对照组，差异具有统计学意义(P<0.05)。结论利拉鲁肽治疗血糖增高的代谢综合征临床疗效显著，其机制可能与增强胰岛素敏感性、减轻胰岛素抵抗、降低体重及调节血清脂联素水平有关。
目的：探討利拉魯肽治療血糖增高的代謝綜閤徵的臨床療效。方法選取2012年1月至2014年1月我院收治的血糖增高的代謝綜閤徵患者192例，按照隨機數字錶法分為觀察組和對照組各96例，觀察組和對照組均給予同樣的飲食和運動方案，觀察組給予利拉魯肽治療，對照組給予二甲雙胍治療，兩組的療程均為3箇月。檢測兩組患者的空腹胰島素、體質指數、血糖、血脂、血清脂聯素等生化指標，計算穩態模型胰島素牴抗指數(HOMA-IR)和總體胰島素敏感指數(WBISI)併進行對比。結果治療前，觀察組和對照組患者在體質指數(BMI)、腰圍(WC)、收縮壓(SBP)、舒張壓(DBP)、空腹血糖(FPG)、餐後2 h血糖(2 hPG)、空腹胰島素(FINS)、甘油三脂(TG)、膽固醇(TC)、高密度脂蛋白-膽固醇(HDL-C)、低密度脂蛋白-膽固醇(LDL-C)、HOMA-IR、WBISI和血清脂聯素方麵比較差異均無統計學意義(P>0.05)；治療後，觀察組和對照組患者以上各指標均較治療前明顯改善，觀察組改善明顯優于對照組，差異具有統計學意義(P<0.05)。結論利拉魯肽治療血糖增高的代謝綜閤徵臨床療效顯著，其機製可能與增彊胰島素敏感性、減輕胰島素牴抗、降低體重及調節血清脂聯素水平有關。
목적：탐토리랍로태치료혈당증고적대사종합정적림상료효。방법선취2012년1월지2014년1월아원수치적혈당증고적대사종합정환자192례，안조수궤수자표법분위관찰조화대조조각96례，관찰조화대조조균급여동양적음식화운동방안，관찰조급여리랍로태치료，대조조급여이갑쌍고치료，량조적료정균위3개월。검측량조환자적공복이도소、체질지수、혈당、혈지、혈청지련소등생화지표，계산은태모형이도소저항지수(HOMA-IR)화총체이도소민감지수(WBISI)병진행대비。결과치료전，관찰조화대조조환자재체질지수(BMI)、요위(WC)、수축압(SBP)、서장압(DBP)、공복혈당(FPG)、찬후2 h혈당(2 hPG)、공복이도소(FINS)、감유삼지(TG)、담고순(TC)、고밀도지단백-담고순(HDL-C)、저밀도지단백-담고순(LDL-C)、HOMA-IR、WBISI화혈청지련소방면비교차이균무통계학의의(P>0.05)；치료후，관찰조화대조조환자이상각지표균교치료전명현개선，관찰조개선명현우우대조조，차이구유통계학의의(P<0.05)。결론리랍로태치료혈당증고적대사종합정림상료효현저，기궤제가능여증강이도소민감성、감경이도소저항、강저체중급조절혈청지련소수평유관。
Objective To investigate the curative effect of Liraglutide in the treatment of hyperglycemia met-abolic syndrome. Methods Totally 192 patients with hyperglycemia metabolic syndrome admitted in our hospital from Jan. 2012 to Jan. 2014 were selected and divided into the observation group and control group (n=96) according to random number table method. Same diet and exercise plan were given to the observation group and control group. Then the observation group was given Liraglutide treatment, while the control group was given metformin treatment. The treatment course was both 3 months. The fasting insulin, body mass index, blood glucose, blood lipid, serum adi- <br> ponectin and other biochemical indicators were detected and compared. The steady-state model of insulin resistance in-dex (HOMA-IR) and whole body insulin sensitivity index (WBISI) were calculated. Results Before treatment, there were no statistically significant differences (P>0.05) between the groups' body mass index (BMI), waist circumference (WC), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting plasma glucose (FPG), 2 h postprandial blood glucose (2 h PG), fasting insulin (FINS), triglycerides (TG), cholesterol (TC), high-density lipoprotein cholester-ol (HDL-C), low density lipoprotein cholesterol (LDL-C), HOMA-IR, WBISI and serum adiponectin;After treatment, the above indexes of the observation group and control group were both obviously improved, and the improved situa-tion of observation group was significantly better than that of the control group. The difference was statistically signifi-cant (P<0.05). Conclusion The curative effect of Liraglutide in treatment of hyperglycemia metabolic syndrome is significant. Enhancing insulin sensitivity, reducing insulin resistance and regulating serum adiponectin level may be the mechanism.
